Latest Schedule 13G passive stakes

Multiple Fourthstone-affiliated investment entities and L. Phillip Stone IV have collectively reported beneficial ownership of approximately 7.01% of First Northern Community Bancorp's common stock.

Two Seas Capital LP, along with its general partner and chief investment officer, has reported beneficial ownership of 2,488,535 shares, representing 6.3% of Quantum Corporation's common stock as of June 30, 2026.

TPG GP A, LLC, along with James G. Coulter and Jon Winkelried, has reported a joint beneficial ownership of 2,975,566 shares, representing 7.8% of Ceribell, Inc.'s common stock.

Multiple Venrock-affiliated entities have reported a complete divestment of their holdings in enGene Holdings Inc. as of June 30, 2026.

Several Fourthstone-affiliated investment entities have collectively reported beneficial ownership of 8.97% of F&M Bank Corp's common stock as of June 30, 2026.

A Schedule 13G filing reveals updated beneficial ownership information for Carter's, Inc. by RWWM, Inc. and associated individuals.

Several Venrock-affiliated entities and individuals have disclosed a combined beneficial ownership of 4.2% of Artiva Biotherapeutics, Inc.'s common stock as of June 30, 2026.

Investment firm Two Seas Capital LP, along with its GP and CIO Sina Toussi, has disclosed beneficial ownership of 3,092,234 shares, representing 9.1% of Nektar Therapeutics' common stock as of June 30, 2026.

Whitefort Capital Management, LP, along with its Co-Managing Partners David Salanic and Joseph Kaplan, now beneficially own 7.1% of OmniAb, Inc. common stock.

Multiple entities associated with Venrock Healthcare Capital Partners have updated their beneficial ownership of Adlai Nortye Ltd. Class A Ordinary Shares.

Investment adviser Fourthstone LLC and affiliated entities have reported beneficial ownership of 329,498 shares, representing 9.14% of Foresight Financial Group Inc.'s common stock.

RA Capital Management, along with its affiliates, has reported a beneficial ownership of 9.9% in Taysha Gene Therapies, Inc., primarily through a significant holding of common stock and pre-funded warrants.

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 4,551,055 shares of Camping World Holdings, Inc. Class A Common Stock, representing 7.16% of the class.

Nantahala Capital Management, LLC, along with principals Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 21,547,895 shares, representing 5.17% of Peloton Interactive, Inc.'s Class A common stock as of June 30, 2026.

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 3,995,579 shares, representing 4.08% of Anteris Technologies Global Corp.'s common stock as of June 30, 2026.

RA Capital Management and its affiliates now beneficially own 9.9% of Ovid Therapeutics' common stock, primarily through warrants and direct holdings, as of June 30, 2026.

Nantahala Capital Management, LLC, along with its managing members, has disclosed beneficial ownership of 7.47% of Immunic, Inc.'s common stock as of June 30, 2026.

Nextech VI Oncology SCSp and related entities have reported beneficial ownership of 6.0% of Tyra Biosciences, Inc. common stock as of June 30, 2026.

RA Capital Management, along with affiliated entities, has reported a beneficial ownership of 9.9% of Karyopharm Therapeutics Inc. common stock as of June 30, 2026.

Nantahala Capital Management, LLC and its principals, Wilmot B. Harkey and Daniel Mack, have reported a 0.00% beneficial ownership of Quince Therapeutics, Inc. common stock as of June 30, 2026.

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 6.75% of Grace Therapeutics, Inc. common stock as of June 30, 2026.

RA Capital Management and its affiliates now beneficially own 9.9% of Geron Corporation's common stock, primarily through RA Capital Healthcare Fund, L.P., following an amendment to their Schedule 13G filing.

RA Capital Management, L.P. and related entities have filed an amendment to their Schedule 13G, reporting zero beneficial ownership of Fulcrum Therapeutics, Inc. common stock as of June 30, 2026.

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 1,862,250 shares, representing 3.54% of Avalo Therapeutics, Inc.'s common stock as of June 30, 2026.

Firefly Aerospace Inc. has filed an amendment to its Schedule 13G, detailing changes in beneficial ownership reporting for AeroEquity GP, LLC, Mitsui & Co., LTD., and Marc Allen Weiser.

Tango Therapeutics, Inc. has filed an amendment to its Schedule 13G, detailing beneficial ownership as of June 30, 2026, with reporting persons holding 0.0% of the class.

Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 4.30% in InhibiKinase Therapeutics, Inc. as of June 30, 2026.

RA Capital Management, along with affiliated entities and individuals, has reported a beneficial ownership of 9.9% in C4 Therapeutics, Inc. as of June 30, 2026, primarily through warrants and common stock.

Caligan Partners LP and David Johnson have reported beneficial ownership of 5.9% of Avalo Therapeutics, Inc. common stock as of June 30, 2026.

Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz have jointly filed a Schedule 13G, reporting no beneficial ownership of Palisade Bio, Inc. common stock as of June 30, 2026.